Ed Arce Recent News
Galectin Shares Downgraded As NASH-FX Failure Likely Degrades The Prognosis For NASH-CX
Wainwright Says Relypsa Takeout Price Is Fair
Aviragen Therapeutics Receives A New Buy Rating, $5 Target
Expect Weakness: H.C. Wainwright Reiterates Buy On Reylpsa
Tobira Therapeutics Shares Initiated With Buy, $22 Target At HC Wainwright
Analyst Sees Relypsa's Valtassa Becoming 'The Standard Of Care,' Initiates With Buy, $63 Target
Conatus Pharma Could Nearly Quadruple, According To H.C. Wainwright Targets
Time To Buy Micro-Cap CymaBay Therapeutics: H.C. Wainwright